UK-based biotechnology company invoX, an international subsidiary established by China-based Sino Biopharmaceutical Group in 2021, is reportedly undergoing a strategic downsizing. The company is focusing its efforts on its lead candidate, the CD137/PD-L1 bispecific molecule FS222, while reducing its workforce. According to Endpoints News, which cited a direct email from invoX, the company will restructure, resulting in 60 job losses, predominantly from the oncology research and development team. This move comes as other projects, including an OX40/CD137 program for solid tumors, a second-generation STING agonist, and a LAG-3/PD-L1 project, are being deprioritized.
FS222 was acquired as part of invoX’s acquisition of F-Star Therapeutics in 2023. The molecule’s early Phase I clinical data were presented at the American Society of Clinical Oncology (ASCO) annual meeting this year, highlighting its potential in the field of oncology.- Flcube.com
